TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| CareFirst, opponents square off over D.C. cash reserves CareFirst BlueCross BlueShield Inc. and health care activists are duking it out Thursday in a hearing to determine if the insurer’s reserves are excessive and should be used to fund health initiatives in D.C. feeds.bizjournals.com |
Stage Set for Acorda Bounce? Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) have hit a five month low, after documents posted on the U.S. Food and Drug Administration's Website show that some agency investigators have questioned whether Acorda's proposed MS treatment Fampridine-SR should be approved.As subscribers to the BioMedReports FDA Calendar know, a special panel is slated to meet next week to discuss whether the agency should approve the drug. The documents were posted ahead of the meeting as part of the agency's briefing materials.Complete Story » seekingalpha.com |
RadNet, Inc. Announces Date of Third Quarter 2009 Earnings Conference Call (GlobeNewswire) LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its third quarter 2009 results on Monday, November 9th, 2009 at 7:30 a.m. us.rd.yahoo.com |
NeoGenomics Announces the Appointment of Jack G. Spitz as Vice President of Laboratory Operations (PR Newswire) NeoGenomics, Inc. announced today that Jack G. Spitz has been appointed Vice President of Laboratory Operations. Â Mr. Spitz will be responsible for managing all laboratory operational affairs of the Company. Â us.rd.yahoo.com |
Sirtris Handles Pfizer's Sirtuin Work Less than Admirably Derek Lowe submits: Nature has a short item on the Pfizer (PFE) paper that questions the reproducibility of some key sirtuin work (covered here and here). There are some good points to temper the pessimism. Leonard Guarente of MIT, a key pioneer in the field, says: ". . . that the latest findings are neither surprising nor worrisome. The compounds may work only with fluorophore-conjugated peptides in vitro, says Guarente, but the situation is different in cells and in animals. The Nature paper, among others, went beyond the test tube and indicated that SIRT1 was more active in cells and in animals after application of the Sirtris (SIRT) compounds. Furthermore, resveratrol administration made no difference to the lifespan of yeast that did not have Sir23, indicating that the compound's action depends on this gene.Complete Story » seekingalpha.com |